Xbrane Biopharma AB XBRANE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- SEK 0.21
- Day Range
- SEK 0.21–0.22
- 52-Week Range
- SEK 0.19–51.49
- Bid/Ask
- SEK 0.21 / SEK 0.22
- Market Cap
- SEK 331.13 Mil
- Volume/Avg
- 5.2 Mil / 21.3 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.22
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Xbrane Biopharma AB is a biotechnology company that develops biosimilars. The company follows drugs on already approved biological drugs that can be introduced at a lower price after the patent expires on the original drug. The company has a patented protein production platform with greater productivity than standard systems for producing proteins in E.coli host cells. Xbrane’s product candidate is Ximluci, a ranibizumab biosimilar (original drug Lucentis) used in the treatment of various eye diseases, mainly the wet form of age-related macular degeneration.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 93
- Website
- https://www.xbrane.com
Comparables
Valuation
|
Metric
|
XBRANE
|
CALTX
|
HNSA
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 0.32 | 17.14 | — |
Price/Sales | 0.22 | 4.75 | 9.20 |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
XBRANE
|
CALTX
|
HNSA
|
|---|---|---|---|
Quick Ratio | 1.04 | 2.85 | 2.57 |
Current Ratio | 1.41 | 3.13 | 2.66 |
Interest Coverage | −16.54 | −5.64 | −7.14 |
Quick Ratio
XBRANE
CALTX
HNSA
Profitability
|
Metric
|
XBRANE
|
CALTX
|
HNSA
|
|---|---|---|---|
Return on Assets (Normalized) | −41.45% | −24.68% | −71.82% |
Return on Equity (Normalized) | −95.00% | −89.92% | — |
Return on Invested Capital (Normalized) | −61.39% | −31.14% | −85.22% |
Return on Assets
XBRANE
CALTX
HNSA
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Ktmdfggbvr | Wjvkz | $578.5 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Yhwbpdbs | Mdvqcr | $101.5 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Cqmnzyhtq | Zbftzj | $98.1 Bil | |
MRNA
| Moderna Inc | Nqcngvc | Hwvzg | $42.2 Bil | |
ARGX
| argenx SE ADR | Sqwlypxs | Xzjn | $22.2 Bil | |
BNTX
| BioNTech SE ADR | Ntdxsnrg | Strd | $21.4 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Zcxhjqdmt | Mkqpln | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Yvxdzzzwz | Nsvksjd | $15.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Ypmztpyyq | Fyqqyff | $12.5 Bil | |
INCY
| Incyte Corp | Vhsymhfdz | Ktffyj | $11.7 Bil |